Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

March 25, 2019

Janssen seeks expanded use of Darzalex combination therapy for patients with newly diagnosed ASCT multiple myeloma

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a Type II variation application to the European Medicines Agency (EMA) for Darzalex (daratumumab) in combination with lenalidomide and dexamethasone (Rd) for the treatment of patients newly diagnosed with multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).

Janssen seeks expanded use of Darzalex combination therapy for patients with newly diagnosed ASCT multiple myeloma